Steven Cohen’s Karyopharm Therapeutics KPTI Stock Holding History

Steven Cohen’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$167K	–	4320
2026 Q1	$167K	Buy	+30,000	New	+$229K	﹤0.01%	3558

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steven Cohen's KPTI Position: Q4 2023 in Review

Steven Cohen sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 18 shares — an estimated $364 sold.

Steven Cohen first reported a position in KPTI in Q2 2014 and held it in 12 quarters. The position peaked at $32.2M in Q4 2017. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

Steven Cohen reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
Steven Cohen sold 18 Karyopharm Therapeutics shares in Q4 2023, an estimated $364.
Steven Cohen first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 12 quarters.
Steven Cohen's Karyopharm Therapeutics position peaked at $32.2M in Q4 2017.
117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.